THE NEW
FRONTIER IN
OPHTHALMIC CARE

What is Glaucoma?

A group of chronic and progressive eye diseases that permanently damage the optic nerve

Elevated eye pressure is the primary and only modifiable risk factor for Glaucoma, the leading cause of irreversible blindness worldwide

Vision loss over time due to Glaucoma

15-20 %

of all Glaucoma patients are at severe stage with
a high risk of permanent
blindness

Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

48.8%

of all mild and moderate patients are worsening
every 12 months

Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

38.1%

of all Glaucoma patients
permanently lose their vision
despite being treated

Why do people (still) go blind from glaucoma?, Susanne et al

Glaucoma is not well controlled for the majority of patients

How is Glaucoma treated?

With prescription eye drops and surgical interventions that can temporarily lower eye pressure.

For every 1 mmHg reduction in eye pressure, the risk of optic nerve damage decreases by 11%

What is the biggest obstacle in Glaucoma management?

Eye pressure (IOP) can only be measured for a few seconds per patient per year giving a very limited understanding of the patient's condition and making Glaucoma a very difficult disease to diagnose and treat.

Our Solutions

Smartlens, Inc. is a platform company aiming to address the biggest challenges in Glaucoma management.

Smartlens' flagship product miLens
is the first device capable of monitoring IOP anywhere, at any time. It is similar to a daily contact lens and will significantly improve Glaucoma management as a
non-invasive, electronics free,
ultra sensitive, and easy to use device.

Smartlens' THERmic applies microdose personalized treatments based on the patient’s diurnal IOP. THERmic can work with all types of Glaucoma medications.

Smartlens owns a broad portfolio of clinical stage technologies that will improve Glaucoma management.

Learn more

THE NEW
FRONTIER IN
OPHTHALMIC CARE

What is Glaucoma?

A group of chronic and progressive eye diseases that permanently damage the optic nerve

Elevated eye pressure is the primary and only modifiable risk factor for Glaucoma, the leading cause of irreversible blindness worldwide

Vision loss over time due to Glaucoma

15-20 %

of all Glaucoma patients are at severe stage with
a high risk of permanent
blindness

Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

48.8%

of all mild and moderate patients are worsening
every 12 months

Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

38.1%

of all Glaucoma patients
permanently lose their vision
despite being treated

Why do people (still) go blind from glaucoma?, Susanne et al

Glaucoma is not well controlled for the majority of patients

How is Glaucoma treated?

With prescription eye drops and surgical interventions that can temporarily lower eye pressure.

For every 1 mmHg reduction in eye pressure, the risk of optic nerve damage decreases by 11%

What is the biggest obstacle in Glaucoma management?

Eye pressure (IOP) can only be measured for a few seconds per patient per year giving a very limited understanding of the patient's condition and making Glaucoma a very difficult disease to diagnose and treat.

Our Solutions

Eye Pressure (IOP) Matters

More than 5 million people are currently being treated for Glaucoma in the U.S., while an estimated 50% of Glaucoma sufferers are undiagnosed

Reducing eye pressure is the only known way of slowing down or stopping the progression of Glaucoma

More than 140 million people are suffering from Glaucoma worldwide; and that number is expected to reach 300 million by 2040

THE NEW FRONTIER IN OPHTHALMIC CARE

What is Glaucoma?

A group of chronic and progressive eye diseases that permanently damage the optic nerve

Elevated eye pressure is the primary and only modifiable risk factor for Glaucoma, the leading cause of irreversible blindness worldwide

Vision loss over time due to Glaucoma

15-20 % of all Glaucoma patients are at severe stage with a high risk of permanent blindness

Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

48.8% of all mild and moderate patients are worsening every 12 months

Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

38.1% of all Glaucoma patients permanently lose their vision despite being treated

Why do people (still) go blind from glaucoma?, Susanne et al

Glaucoma is not well controlled for the majority of patients

How is Glaucoma treated?

With prescription eye drops and surgical interventions that can temporarily lower eye pressure.

For every 1 mmHg reduction in eye pressure, the risk of optic nerve damage decreases by 11%

What is the biggest obstacle in Glaucoma management?

​

Eye pressure (IOP) can only be measured for a few seconds per patient per year giving a very limited understanding of the patient's condition and making Glaucoma a very difficult disease to diagnose and treat.

Our Solutions

Eye Pressure (IOP) Matters

More than 5 million people are currently being treated for Glaucoma in the U.S., while an estimated 50% of Glaucoma sufferers are undiagnosed ​​

​Reducing eye pressure is the only known way of slowing down or stopping the progression of Glaucoma

More than 140 million people are suffering from Glaucoma worldwide; and that number is expected to reach 300 million by 2040

THE NEW
FRONTIER IN
OPHTHALMIC CARE

15-20 %

of all Glaucoma patients are at severe stage with
a high risk of permanent
blindness

48.8%

of all mild and moderate patients are worsening
every 12 months

38.1%

of all Glaucoma patients
permanently lose their vision
despite being treated

More than 5 million people are currently being treated for Glaucoma in the U.S., while an estimated 50% of Glaucoma sufferers are undiagnosed

Reducing eye pressure is the only known way of slowing down or stopping the progression of Glaucoma